Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 13299-99-5
2. 6-(3-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)pyridazin-3(2h)-one Hydrochloride
3. Mat2a Inhibitor 2
4. 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-3(2h)-pyridazinone Hydrochloride
5. Azg477hc22
6. Ag270
7. Run99995
8. 13299-99-5 (hcl)
9. Ag 270
10. Morpholinoethyl-2 Methyl-4 (m-methoxyphenyl)-6 Pyridazone-3 Chlorhydrate [french]
11. Unii-azg477hc22
12. Ag-270(mat2a Inhibitor 1)
13. Dtxsid20157888
14. Ag-270 (mat2a Inhibitor 1)
15. Ex-a5020
16. Mfcd01692601
17. Akos037648686
18. Morpholinoethyl-2 Methyl-4 (m-methoxyphenyl)-6 Pyridazone-3 Chlorhydrate
19. 3(2h)-pyridazinone, 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-, Monohydrochloride
20. Bs-15201
21. Hy-112569
22. Cs-0046765
23. N17040
24. 6-(3-methoxyphenyl)-4-methyl-2-(2-morpholin-4-ylethyl)pyridazin-3-one;hydrochloride
25. 6-(3-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)pyridazin-3(2h)-one Xhydrochloride
26. 6-(3-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)pyridazin-3(2h)-onehydrochloride
27. 14660-66-3
28. 6-(3-methoxyphenyl)-4-methyl-2-(2-(4-morpholinyl)ethyl)-3(2h)-pyridazinone Hydrochloride
| Molecular Weight | 365.9 g/mol |
|---|---|
| Molecular Formula | C18H24ClN3O3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 5 |
| Exact Mass | 365.1506193 g/mol |
| Monoisotopic Mass | 365.1506193 g/mol |
| Topological Polar Surface Area | 54.4 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 512 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
ABOUT THIS PAGE
85
PharmaCompass offers a list of 3(2H)-Pyridazinone, 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-, hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right 3(2H)-Pyridazinone, 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-, hydrochloride manufacturer or 3(2H)-Pyridazinone, 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-, hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred 3(2H)-Pyridazinone, 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-, hydrochloride manufacturer or 3(2H)-Pyridazinone, 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-, hydrochloride supplier.
PharmaCompass also assists you with knowing the 3(2H)-Pyridazinone, 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-, hydrochloride API Price utilized in the formulation of products. 3(2H)-Pyridazinone, 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-, hydrochloride API Price is not always fixed or binding as the 3(2H)-Pyridazinone, 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-, hydrochloride Price is obtained through a variety of data sources. The 3(2H)-Pyridazinone, 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-, hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A AKOS037648686 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of AKOS037648686, including repackagers and relabelers. The FDA regulates AKOS037648686 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. AKOS037648686 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A AKOS037648686 supplier is an individual or a company that provides AKOS037648686 active pharmaceutical ingredient (API) or AKOS037648686 finished formulations upon request. The AKOS037648686 suppliers may include AKOS037648686 API manufacturers, exporters, distributors and traders.
AKOS037648686 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of AKOS037648686 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right AKOS037648686 GMP manufacturer or AKOS037648686 GMP API supplier for your needs.
A AKOS037648686 CoA (Certificate of Analysis) is a formal document that attests to AKOS037648686's compliance with AKOS037648686 specifications and serves as a tool for batch-level quality control.
AKOS037648686 CoA mostly includes findings from lab analyses of a specific batch. For each AKOS037648686 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
AKOS037648686 may be tested according to a variety of international standards, such as European Pharmacopoeia (AKOS037648686 EP), AKOS037648686 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (AKOS037648686 USP).
